299 related articles for article (PubMed ID: 30522722)
1. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
Vachiéry JL; Galiè N; Barberá JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Blair C; Miller KL; Langley J; Rubin LJ;
J Heart Lung Transplant; 2019 Feb; 38(2):194-202. PubMed ID: 30522722
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.
White RJ; Vonk-Noordegraaf A; Rosenkranz S; Oudiz RJ; McLaughlin VV; Hoeper MM; Grünig E; Ghofrani HA; Chakinala MM; Barberà JA; Blair C; Langley J; Frost AE
Respir Res; 2019 Sep; 20(1):208. PubMed ID: 31511080
[TBL] [Abstract][Full Text] [Related]
3. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
[TBL] [Abstract][Full Text] [Related]
4. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
Hoeper MM; McLaughlin VV; Barberá JA; Frost AE; Ghofrani HA; Peacock AJ; Simonneau G; Rosenkranz S; Oudiz RJ; White RJ; Miller KL; Langley J; Harris JHN; Blair C; Rubin LJ; Vachiery JL
Lancet Respir Med; 2016 Nov; 4(11):894-901. PubMed ID: 27745818
[TBL] [Abstract][Full Text] [Related]
5. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG
Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055
[TBL] [Abstract][Full Text] [Related]
6. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
[TBL] [Abstract][Full Text] [Related]
7. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial.
McLaughlin VV; Vachiery JL; Oudiz RJ; Rosenkranz S; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Peacock AJ; Simonneau G; Rubin LJ; Blair C; Langley J; Hoeper MM;
J Heart Lung Transplant; 2019 Dec; 38(12):1286-1295. PubMed ID: 31648845
[TBL] [Abstract][Full Text] [Related]
8. Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension.
Hatano M; Abe K; Koike G; Takahashi T; Tunmer G; Kiely DG
Int Heart J; 2022; 63(1):99-105. PubMed ID: 35095084
[TBL] [Abstract][Full Text] [Related]
9. Ambrisentan: a review of its use in pulmonary arterial hypertension.
Rivera-Lebron BN; Risbano MG
Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
[TBL] [Abstract][Full Text] [Related]
10. Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score.
Frost AE; Hoeper MM; Barberá JA; Vachiery JL; Blair C; Langley J; Rubin LJ
J Heart Lung Transplant; 2018 Dec; 37(12):1410-1417. PubMed ID: 30209017
[TBL] [Abstract][Full Text] [Related]
11. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
[TBL] [Abstract][Full Text] [Related]
12. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
Abston E; Hon S; Lawrence R; Berman J; Govender P; Farber HW
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):234-238. PubMed ID: 33093789
[TBL] [Abstract][Full Text] [Related]
13. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).
D'Alto M; Romeo E; Argiento P; Paciocco G; Prediletto R; Ghio S; Correale M; Lo Giudice F; Badagliacca R; Greco A; Vizza CD
J Cardiovasc Med (Hagerstown); 2018 Jan; 19(1):12-17. PubMed ID: 29215546
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
[TBL] [Abstract][Full Text] [Related]
15. Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
Mandras S; Kovacs G; Olschewski H; Broderick M; Nelsen A; Shen E; Champion H
J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):453-462. PubMed ID: 33836637
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil.
Escribano Subías P; Aurtenetxe Pérez A; Pérez Olivares C; Gómez Climent L; Diago Cabezudo JI; Perelló MF
Expert Rev Respir Med; 2021 Apr; 15(4):493-504. PubMed ID: 33472458
[TBL] [Abstract][Full Text] [Related]
17. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
Oudiz RJ; Galiè N; Olschewski H; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Harrison BC; Despain D; Dufton C; Rubin LJ;
J Am Coll Cardiol; 2009 Nov; 54(21):1971-81. PubMed ID: 19909879
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience.
Issapour A; Frank B; Crook S; Hite MD; Dorn ML; Rosenzweig EB; Ivy DD; Krishnan US
Pediatr Pulmonol; 2022 Mar; 57(3):724-733. PubMed ID: 34921523
[TBL] [Abstract][Full Text] [Related]
19. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
[TBL] [Abstract][Full Text] [Related]
20. Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.
Fauvel C; Liu Y; Correa-Jaque P; Kanwar MK; Vizza CD; Lin S; Benza RL
Chest; 2023 Dec; 164(6):1518-1530. PubMed ID: 37356711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
